Dr. Buchanan has led the institutional pediatric and research
sickle cell disease programs for 37 years.
Not exact matches
To assess risk, Thomas Adamkiewicz, codirector of the Hemoglobinopathy / Genomics Training
Program at Morehouse School of Medicine in Atlanta, surveyed four medical centers and found that seven children with
sickle -
cell disease had been treated with umbilical cord blood from unrelated donors.
But there's a great deal of overlap: For example, CRISPR Therapeutics and Editas have both made
sickle cell disease and Duchenne muscular dystrophy a priority, and Intellia and Editas both have
programs targeting the liver
disease α - 1 antitrypsin deficiency and collaborations that focus on engineering T
cells to fight cancer.
Prompted by health officials with a dim sense of genetics, the testing of African Americans for
sickle -
cell disease was a social
program that, like the Tuskegee study, backfired on the group it was meant to benefit.
Kenneth Ataga, MD, director of the UNC Comprehensive
Sickle Cell Program, was featured in a video by the American Society of Hematology in which he discussed the favorable results of a yearlong clinical trial studying crizanlizumab as a therapy to prevent and treat painful crisis events in patients with sickle cell di
Sickle Cell Program, was featured in a video by the American Society of Hematology in which he discussed the favorable results of a yearlong clinical trial studying crizanlizumab as a therapy to prevent and treat painful crisis events in patients with sickle cell dise
Cell Program, was featured in a video by the American Society of Hematology in which he discussed the favorable results of a yearlong clinical trial studying crizanlizumab as a therapy to prevent and treat painful crisis events in patients with
sickle cell di
sickle cell dise
cell disease.
Colleen Dansereau, RN, MSN, CPN
Program Manager, Gene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
Program Manager, Gene Therapy
Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
Program As manager of the Gene Therapy
Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
Program, Colleen administratively manages the CAR T -
cell therapy
program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease
program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including
sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous
disease (CGD).
Dr. Haywood also serves as a member of the oversight steering committee for the Health Resources and Services Administration's
Sickle Cell Disease Treatment Demonstration
Program.
The Bone Marrow and Stem
Cell Transplant Program is expanding the use of this technique for patients with solid tumors including neuroblastoma and brain tumors; a variety of high - risk hematologic diseases, such as thalassemia major and transfusion - dependent sickle cell disease; and other nonmalignant disea
Cell Transplant
Program is expanding the use of this technique for patients with solid tumors including neuroblastoma and brain tumors; a variety of high - risk hematologic
diseases, such as thalassemia major and transfusion - dependent
sickle cell disease; and other nonmalignant disea
cell disease; and other nonmalignant
diseases.
Children receiving care at Texas Children's
Sickle Cell Program have the opportunity to participate in several National Institutes of Health (NIH)- funded research studies led by physician scientists, providing the latest treatments for this
disease.
The
Sickle Cell Program conducts state - of - the - art clinical and laboratory research aimed at gaining a better understanding of the
disease, preventing its complications and ultimately finding a cure.
But the one that I am most proud of is the development (clinical trial) of the first and only remote telephonic mindfulness - based stress reduction
program for individuals with
Sickle Cell Disease and chronic pain.